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The objective of this study was to characterize the pharmacokinetics of unbound and
total concentrations of daptomycin in infected ICU patients with various degrees of
renal impairment. From these results, the probability of attaining antimicrobial
efficacy and the risks of toxicity were assessed.
Methods
Twenty-four ICU patients with various renal functions and requiring treatment of
complicated skin and soft-tissue infections, bacteraemia, or endocarditis with
daptomycin were recruited. Daptomycin (Cubicin®) at 10 mg/kg was administered
every 24 h for patients with creatinine clearance (CLCR) ≥30 mL/min and every 48 h
for patients with CLCR <30 mL/min. Total and unbound plasma concentrations and
urine concentrations of daptomycin were analysed simultaneously following a
population pharmacokinetic approach. Simulations were conducted to estimate the
probability of attaining efficacy (unbound AUCu/MIC >40 or >80) or toxicity (Cmin
>24.3 mg/L) targets.
Results
Exposure to unbound daptomycin increased when the renal function decreased, thus
increasing the probability of reaching the efficacy targets, but also the risk of toxicity.
Modifications of the unbound fraction (fu) of daptomycin did not affect the
pharmacokinetics of unbound daptomycin, but did affect the pharmacokinetics of total
daptomycin.
Conclusions
Daptomycin at 10 mg/kg q24h allowed efficacy pharmacokinetic/pharmacodynamic
targets for ICU patients with CLCR ≥30 mL/min to be reached. For patients with
CLCR <30 mL/min, halving the rate of drug administration, i.e. 10 mg/kg q48h, was
sufficient to reach these targets. No adverse events were observed, but the toxicity of
the 10 mg/kg q24h dosing regimen should be further assessed, particularly for
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